Anti-von Willebrand factor (vWF) monoclonal antibody NMC-4 completely inhibited vWF binding t o platelet glycoprotein (GP) Ib induced by either ristocetin or botrocetin at an IgG concentration of -10 pg/mL, and also blocked binding of asialo-vWF t o GP Ib. NMC-4 coupled beads isolated a 97-Kd fragment (Fr) from a whole tryptic digest of vWF. The N-terminal sequencing of the nonreduced 97-Kd Fr, in combination with amino acid analysis, showed it t o be a homodimer of residues 449 through 728 of the constituent subunit. Present data, together with the results obtained from previous studies, confirm the existence of one or three possible inter-subunit disulfide bonds between cysteine residues 459,462, and 464. NMC-4 bound t o reduced vWF Fr(s) more weakly than t o nonreduced Fr(s), but it did not react ON WILLEBRAND factor (vWF) is a plasma glycopro-
V tein (GP) that circulates in blood as a series of multimers, in association with factor VI11 procoagulant protein. At high shear stress, vWF mediates platelet adhesion to sites of vascular injury.'.' It is now well established that interaction of vWF with platelet GP Ib is an initial step in this process. The antibiotic ristocetin induces vWF binding to GP Ib and mimics this event in vitro: Botrocetin, a compound derived from snake venom, also acts as an agonist to mediate this interaction in vitro?. 6 The GP Ib binding domain(s) of vWF, similarly expressed by ristocetin and botrocetin, has been shown to reside on a reduced and alkylated 52/48-Kd tryptic fragment (Fr) of vWF that corresponds to amino acid residues Va1449-Lys728 of the s u b~n i t .~.~ More recently, studies using synthetic peptides precisely localized the ristocetin-dependent GP Ib binding domain of vWF on two noncontiguous sequences, Cys474-Pro488 and Leu694-Pro708." Unpublished data from this laboratory show that synthetic peptides corresponding to Cys474-Pro488 and Leu694-Pro708 selectively inhibited ristocetin-induced vWF binding, but had no effect on botrocetin-induced binding. These findings suggest that the GP Ib binding domains expressed by ristocetin and botrocetin are not identical, and support a previous finding on characteristics of an antibody causing acquired von Willeband syndrome."
An anti-vWF monoclonal antibody (MoAb) (NMC-4) prepared in this laboratory was recently shown to inhibit ristocetin-induced vWF binding.10,'2 We now demonstrate that NMC-4 inhibits botrocetin-induced vWF binding to platelets, and also blocks binding of asialo-vWF to platelets. Thus, NMC-4 appears to recognize the GP Ib binding domain(s) of vWF, which is similarly expressed by these different inducers. Our results suggest that NMC-4 binds to reduced vWF Fr(s) more weakly than to nonreduced Fr(s), and that region Leu512-Lys673 is important for this binding. This same region plays a key role in botrocetin-induced vWF binding to platelets, as suggested by another method of study using polypeptides derived from subdigestion of the reduced and alkylated 52148-Kd Fr.
with Fr lll-T2 of vWF, a disulfide-linked twin heterodimer of residues 273 through 511 and 674 through 728 (Matti et al, Biochemistry 26:8099, 1987) . Fr WT2 completely inhibited ristocetin-induced vWF binding at a concentration of 100 pmol/L but had no effect on botrocetin-induced binding. In addition, both the N-and C-terminal polypeptides, residues 449 through 549 and 674 through 728, generated by subdigestion of the 52/48-Kd Fr (Fujimura et 9 , with 20 pg of lysylendopeptidase at 37°C for 6 hours. The resultant peptides were fractionated on two size exclusion high performance liquid chromatography (HPLC) columns (TSK G3000 SW, Tosoh, Tokyo, Japan), highly purified by reversed-phase HPLC on Syn Chropak RP-8 (Syn Chrom Inc, Lafayette, IN), and lyophilized to characterize through amino acid analysis. The lyophilized peptides were then solubilized in 4 mol/L urea/0.05 m o m Tris-HC1, pH 7.35, to give a concentration of 1,000 FmoK, and used as competing ligands for vWF binding assays as described in Results.
MoAb NMC-4 (IgG,-K) was prepared in this laboratory.'* MoAb RFF-VII1RAG:l (IgG,-K) was kindly provided by Dr E.G.D. Tuddenham (Clinical Research Center, Middlesex, UK) and was characterized previously." MoAbs RG46,52K-S, and 2-2-9 (all IgG,-K) were provided by Drs Z.M. Ruggeri and T.S. Zimmerman (Scripps Clinic, La Jolla, CA). Igs were purified on a protein A-Sepharose CL-6B column by the method of Ey et a1.'* All the anti-vWF MoAbs described here, except for 2-2-9, inhibited ristocetin-induced vWF binding (see Results). The epitope of MoAb 2-2-9 was determined to reside on the C-terminal Fr I1 generated by V8 protease digestion of vWF.
In a typical experiment, lyophilized vWF (100 mg) was dissolved in 50 mL of 0.1 m o m NH,HCO,, pH 7.8, then digested with bovine pancreatic trypsin at an enzyme:substrate (E/S) ratio of 1/50 (wt/wt) for 2 hours at 37°C. Sodium dodecyl sulfate 5% to 20% exponential gradient polyacrylamide gel electrophoresis (SDS-PAGE) was performed by the method of Laemmli.'' Molecular weight (Mr) was determined using BioRad HMW and LMW kits (BioRad, Richmond, CA); myosin (200 Kd), P-galactosidase (116 Kd), phosphorylase b (97 Kd), BSA (66 Kd), ovalbumin (43 Kd), carbonic anhydrase (31 Kd), soybean trypsin inhibitor (22 Kd), and lysozyme (14 Kd). Protein staining, Western blotting followed by autoradiography, and electroelution were performed as described previously. ' Amino acid compositions were determined by the Waters Pic0 tag system of Bidlingmeyer et alZo after 24-hour acid hydrolysis of peptides. N-terminal sequences were
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determined with an Applied Biosystems 470A Protein Sequencer (Applied Biosystems, Foster City, CA) after blotting onto polyvinylidene difluoride (PVDF) membrane."
A microplate (Falcon 3912 microtest I11 flexible assay plate; Becton Dickinson, Oxnard, CA) assay was used. Each microwell was coated with 50 pL of IgG (50 pg/mL) purified from anti-vWF MoAb 2-2-9 dissolved in 0.1 mol/L bicarbonate buffer, pH 9.6, overnight at 4"C, and then blocked with 4% BSA for 2 hours. After washing three times with phosphate-buffered saline (PBS), pH 7.4, 50 pL of purified vWF (50 pg/mL) in PBS was added to each well and left For personal use only. on November 11, 2017. by guest www.bloodjournal.org From overnight at 4°C. After washing three times again with PBS, ['"I]NMC-4 (0.14 kg IgG/mL) with or without competing ligands was added to each well and incubated at 4°C overnight. Finally, wells were washed three times with PBS containing 0.1% BSA. The radioactivity bound to solid-phase vWF was measured by a gamma counter after wells were cut out with a scalpel. Nonspecific binding was determined in the presence of a 50-fold excess of unlabeled NMC-4 (IgG).
Binding of ['2sI]NMC-4 (IgG
RESULTS
Inhibition of vWF or AS-v WF binding to GP Ib by NMC-4.
MoAb NMC-4 completely inhibited both ristocetin-and botrocetin-induced vWF binding, as well as AS-vWF binding, to platelet G P Ib at an IgG concentration of less than 10 pg/mL (Fig 1) .
Immunoreactivity of tryptic v WF Frs generated at various E/S ratios by NMC-4. Aliquots of vWF (33 pg) dissolved in 50 p L of 0.1 mol/L NH,HCO,H, pH 7.8, were digested for 2 hours at 37°C by bovine trypsin at various E/S ratios ranging from 1/500 to 1/50. Each sample was subjected to SDS 5% to 20% PAGE under nonreducing or reducing conditions, followed by Western blotting. NMC-4 binding to tryptic vWF Frs was detected by autoradiography using ["'Ilantimouse IgG. NMC-4 reacted with both nonrcduccd and reduced Frs, but the lattcr were less immunoreactive than the former. In the nonreduccd gel, two major bands with Mr 130 and 97 Kd were detected at E/S ratio 1/100, while a nearly single band with Mr 97 Kd was found at E/S ratio 130 97 1/50. In the reduced gel, two major bands with Mr 74 and 52/48 Kd were found at E/S ratio 1/100, and a homogenous 52/48-Kd band at WS ratio of 1/50 (Fig 2) . Immrinoisolation and purity analysis of a tryptic 97-Kd Fr of vWF. As described in Materials and Methods, a 97-Kd tryptic Fr of vWF was immunoisolated by NMC-4 coupled sepharose column. Further purification was achieved by HPLC Ultrapore RPSC (C3) column. As shown in Fig 3, a major single peak was shown by acetonitrile gradient elution. The purified protein showed a homogeneous 97-Kd Fr on nonreduced SDS-PAGE (see Fig 5A, lane 1) and a 52/48-Kd doublet Fr on reduced SDS-PAGE, as expected (see Fig 5B, lane 1) . The N-terminal sequence of the nonreduced 97-Kd Fr was shown to be Val-Thr-Leu-X-ProScr (Table I) , which corresponded to residues Val449 through Ser454 of the vWF subunit." This finding, together with amino acid composition data (Table I) , strongly suggested that the 97-Kd Fr was a homodimer of residues Val449 through Lys728 of the vWF subunit.
Competitive effect of the 97-Kd Fr on vWF or AS-vWF binding to GP Ib. The homodimeric 97-Kd Fr was used as a competing ligand on ristocetin-or botrocetin-induced vWF binding to G P Tb, and the inhibitory effects were compared with those of the monomeric S-CM 52/48-Kd Fr. The 97-and 52/48-Kd Frs inhibited both types of vWF binding at similar molar concentrations (Fig 4A and B) , and also completely blocked AS-vWF binding (Fig 4C) values in each case were within the same range, indicating that the 97-Kd Fr also bound directly to GP Ib. Three vWF Frs were used in this study. The homodimeric 97-Kd Fr was purified as described above. The 130-Kd Fr shown in Fig 5 ( To avoid a possible denaturing effect of SDS on protein conformation, a dot-blot assay was performed using SDSfree nonreduced purified polypeptides. N-terminal Fr I11 was strongly immunoreactive with NMC-4, but the C-tcrminal Fr I1 (used as control) was poorly reactive. The nonreduced 97-Kd Fr was moderately immunoreactive, but again Fr 111-T2 showed no reactivity with NMC-4 (Fig 7) .
Effect of lysyl end cleavedpolypeptides of S-CM 52148-Kd Fr on vWF binding. Lysyl end cleavage of the S-CM 52148-Kd Fr followed by HPLC separation yielded eight unrelated complete inhibition at 100 p,mol/L), but had no effect on botrocetin-induced vWF binding (Fig 6) .
As shown in Fig SA, NMC-4 was strongly immunoreactive with both the 97-and 130-Kd Frs on Western blotting under nonreducing conditions, but not immunorcactive with Fr 111-T2. Under reducing conditions (Fig 5B) , NMC induced vWF binding. Eight unrelated polypeptides were tested as competing ligands at a final concentration of 100 kmol/L. Two polypeptides (amino acid sequences 449 through 549 and 674 through 728) showed a significant inhibition of ristocetin-induced vWF binding, but they had no effect on botrocetin-induced vWF binding (see Results). The assay systems were the same as described in Fig 6. peptides: the amino acid sequences 449 through 549, 550 through 569,573 through 585,586 through 599,600 through 608, 609 through 643, 646 through 660, and 674 through 728. Because these peptides were dissolved in 4 mol/L urea (see Materials and Methods), the vWF binding assays were performed in the presence of 0.4 mol/L urea. Under these conditions maximal concentration of the peptides attainable was 100 pmol/L.
As shown in Fig 8, both the N-terminal(449 through 549) and the C-terminal (674 through 728) polypeptides inhibited ristocetin-induced vWF binding by 95% and 98%, respectively, at a final concentration of 100 kmol/L, whereas none of the eight peptides produced significant inhibition of botrocetin-induced vWF binding as determined at two concentrations of 10 and 100 pmol/L. The inhibitory effect of the N-terminal(449 through 549) or the C-terminal(674 through 728) polypeptide on ristocetin-induced binding was in a dose-dependent manner at concentrations between 6.6 pmol/L and 100 pmol/L, but neither of them had significant inhibition on botrocetin-induced binding within this range of concentration (Fig 9) . No synergistic binding inhibition by the two polypeptides was observed on these two binding assays (data not shown).
Two MoAbs, RG46 and 52K-8, which recognize the S-CM 52/48-Kd Fr and inhibit ristocetin-induced vWF binding,'.'' had no effect on botrocetin-induced binding, and showed distinct immunoreactivity with the sequences 449 through 549 and 674 through 728 on Western blotting (data not shown).
To compare binding site localization of three anti-vWF MoAbs that had been shown to inhibit ristocetin-induced vWF binding, a solid-phase assay using ['zI]NMC-4 was performed (Fig  10) . botrocetin and vWF form an activated complex which then binds to GP Ib. It remains to be investigated whether the inhibition of botrocetin-induced binding by NMC-4 is due to interference with formation of this activated complex. Western blotting studies show that NMC-4 reacts with both the nonreduced and reduced vWF Frs generated by trypsin digestion. However, a smaller quantity of NMC-4 is bound in the latter case, suggesting that the MoAb recognizes a conformation epitope on the vWF molecule rather than a linear amino acid sequence.
A 97-Kd tryptic vWF Fr, purified by NMC-4 coupled Sepharose column, was characterized here in detail based an amino acid analysis, and was shown to be a homodimer of the sequence Va1449-Lys728 of the vWF subunit. The Mr of this polypeptide was almost the same as that reported by Pareti et alz5 with 96-Kd Fr, which was isolated from a whole tryptic digest of vWF by means of ion-exchange HPLC and molecular sieve HPLC. However, they only demonstrated that the 96-Kd Fr was a homodimer of residue 449 through 728 based on SDS-PAGE analysis and immunoblotting studies with anti-vWF MoAb reacting with cyanogen bromide fragment M9 (residues 293 through 540 of the vWF subunit). In addition, there are strict analogies between the results recently reported by Mohri et aIz6 with the 116-Kd Fr and those obtained here with 97-Kd Fr (and probably those obtained by Pareti et al with 96-Kd Fr as well). We have clearly shown here that a homodimer of residues 449 through 728 can be produced by an extensive trypsin digestion of vWF. Mohri et aIz6 described the use of a much lesser amount of trypsin in the preparation of 116-Kd Fr, but they did not show any evidence that the Fr was characterized on the basis of the amino acid analysis. Thus, the reasons for the difference in estimated Mr between 116 Kd and 97 Kd are presently unknown. Besides, it is likely that the 116-Kd Fr has a slightly different molecular structure from that of the 97-Kd Fr, because the former appears to have more biologic activities in promoting in vitro vWF-GP Ib interaction than the latter because the assay systems used in the two studies are comparable.
In an attempt to localize the NMC-4 epitope more precisely, a second cleavage of the 97-Kd Fr using various enzymes or cyanogen bromide was performed, but without success. As an alternative procedure, Fr 111-T2, a twin heterodimer composed of two H-chains (Lys273-Arg5 11) and two L-chains (Ala674-Lys728) held together by disulfide bonds, was prepared and used. In agreement with the previous finding of Marti et a1,16 FIII-T2 retained the inhibitory effect on ristocetin-induced vWF binding to GP Ib. We have further shown that Fr 111-T2 does not retain the inhibitory activity on botrocetin-induced vWF binding. MoAb NMC-4 showed no reactivity with Fr 111-T2 under natured or SDS-denatured conditions in agreement with the findings of Mohri et aLZ6 Therefore, it is likely that the immunoreactivity of NMC-4 disappears concomitantly with a loss of the competing effect on botrocetin-induced rather than ristocetin-induced vWF binding.
Marti et all6 identified nine disulfide pairings within Fr 111-T2, but only four of them could be demonstrated to be intrachain. Of those present within the sequence 449 through 728 in particular, the parings of cysteine residues 471 through 474 and 509 through 695 without defining were demonstrated. However, Mohri et allo first supported, and later Andrews et aIz7 demonstrated that residues 509 through 695 also are paired in an intrachain bond. Because existence of free cysteine residues was not detected within the vWF subunit by other one or three possible intersubunit disulfide bonds must exist on cysteine residues 459,462, and 464 of the vWF subunit.
Competitive binding studies using ['zI]NMC-4 showed that its binding to vWF was not blocked by MoAb RG46 or 52K-8, which recognizes sequences Va1449-Lys549 and Ala674-Lys728 respectively; however, each MoAb preferentially blocked ristocetin-induced vWF binding. MoAb RFF-VIIIRAG:l, which incompletely blocked botrocetin-induced vWF binding, showed partial competitive binding inhibition of NMC-4. Although this finding must be evaluated with caution because the binding affinities of the MoAbs to vWF are different, it does strengthen the concept that the botrocetin-induced and ristocetin-induced vWF binding domains are expressed differently. Our results also suggest that sequence Leu512-Lys673 is important for both botrocetin-induced vWF binding to GPIb and NMC-4 binding to vWF. These hypotheses are indirectly supported by another line of evidence that lysyl end cleaved polypeptides unambiguously positioned the ristocetin-dependent binding domain on two noncontiguous regions as it was suggested using synthetic peptides," whereas neither lysyl end-cleaved polypeptides nor the two synthetic peptides significantly inhibited botrocetin-induced binding. For personal use only. on November 11, 2017. by guest www.bloodjournal.org From
